Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
26 03 2019
Historique:
received: 10 09 2018
accepted: 03 02 2019
entrez: 20 3 2019
pubmed: 20 3 2019
medline: 28 3 2020
Statut: ppublish

Résumé

Osteopetrosis (OP) is a rare disease caused by defective osteoclast differentiation or function. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available in the infantile "malignant" form of OP. Improved clinical and genetic diagnosis of OP has seen the emergence of a cohort of patients with less severe and heterogeneous clinical presentations. This intermediate form of OP does not call for urgent intervention, but patients accumulate debilitating skeletal complications over years and decades, which are severe enough to require curative treatment and may also require intermittent transfusion of blood products. Here we present data from 7 patients with intermediate OP caused by mutations in

Identifiants

pubmed: 30885997
pii: bloodadvances.2018025890
doi: 10.1182/bloodadvances.2018025890
pmc: PMC6436016
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

862-868

Informations de copyright

© 2019 by The American Society of Hematology.

Références

J Med Genet. 2012 Apr;49(4):221-6
pubmed: 22499339
J Bone Miner Res. 2003 Oct;18(10):1740-7
pubmed: 14584882
Pediatr Blood Cancer. 2016 Mar;63(3):535-40
pubmed: 26485304
Pediatr Transplant. 1999;3 Suppl 1:102-7
pubmed: 10587979
J Bone Miner Res. 2014 Jul;29(7):1646-50
pubmed: 24535816
Blood. 2015 Jul 9;126(2):270-6
pubmed: 26012570
Br J Haematol. 2004 Jan;124(1):63-71
pubmed: 14675409
Bone Marrow Transplant. 2006 Oct;38(8):547-53
pubmed: 16953210
Am J Hum Genet. 2008 Jul;83(1):64-76
pubmed: 18606301
Eur J Hum Genet. 2009 May;17(5):664-72
pubmed: 19172990
Pediatr Transplant. 2015 Jun;19(4):422-7
pubmed: 25879376
N Engl J Med. 2004 Dec 30;351(27):2839-49
pubmed: 15625335
N Engl J Med. 2012 Nov;367(18):1766-7
pubmed: 23113501
Nat Rev Endocrinol. 2013 Sep;9(9):522-36
pubmed: 23877423

Auteurs

Polina Stepensky (P)

Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel.

Sigal Grisariu (S)

Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel.

Batia Avni (B)

Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel.

Irina Zaidman (I)

Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel.

Bella Shadur (B)

Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel.
Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Graduate Research School, University of New South Wales, Sydney, NSW, Australia.

Orly Elpeleg (O)

Monique and Jacques Roboh Department of Genetic Research, Hadassah-Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel; and.

Mehtap Sirin (M)

Department of Pediatrics and Adolescent Medicine.

Manfred Hoenig (M)

Department of Pediatrics and Adolescent Medicine.

Catharina Schuetz (C)

Department of Pediatrics and Adolescent Medicine.

Ingrid Furlan (I)

Department of Pediatrics and Adolescent Medicine.

Meinrad Beer (M)

Department of Radiology, and.

Stephanie von Harsdorf (S)

Department of Internal Medicine III, University Medical Center Ulm, Ulm, Germany.

Donald Bunjes (D)

Department of Internal Medicine III, University Medical Center Ulm, Ulm, Germany.

Klaus-Michael Debatin (KM)

Department of Pediatrics and Adolescent Medicine.

Ansgar S Schulz (AS)

Department of Pediatrics and Adolescent Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH